Merck and Moderna announced positive Phase 3 results for intismeran autogene, an mRNA personalized cancer vaccine, combined with Keytruda in melanoma. The trial met recurrence-free and distant metastasis-free survival endpoints. Full data to be presented at a medical meeting; regulatory submissions to begin.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
